From sandbox to pandemic: Agile reform of Canadian drug regulation

Eren Vural, İpek
Herder, Matthew
Graham, Janice E.
© 2021Public health urgency for emerging COVID-19 treatments and vaccines challenges regulators worldwide to ensure safety and efficacy while expediting approval. In Canada, legislative amendments by 2019 Omnibus Bill C-97 created a new "agile" licensing framework known as the "Advanced Therapeutic Pathway" (ATPathway) and modernized the regulation of clinical trials of drugs, vaccines, and medical devices. Bill C-97′s amendments are worthy of attention in Canada and globally, as health product regulation bends to COVID-19. The amendments follow reforms elsewhere to accommodate health product innovation, however, the Canadian ATPathway is broader and more flexible than its counterparts in other jurisdictions. In addition, Bill C-97 informed Canada's COVID-19 response in important ways, particularly in relation to clinical trials. The measures adopted by the drug regulatory authority, Health Canada (HC) during COVID-19 may become the new norm in Canadian regulatory practice insofar as they help achieve the amendments introduced by Bill C-97. Finally, despite government rhetoric of transparency, the agenda-setting, formulation, and implementation of the amendments have occurred with little opportunity for scrutiny or public engagement.


Peptide-based drug systems /
Parlak, Melek; Özçubukçu, Salih; Department of Chemistry (2017)
The increasing appeal of safe, cheap and effective treatments against various type of diseases has paved the way for the discovery and development of innovative peptide-based drug and drug delivery systems. The relative ease with which peptide based-materials can be synthesized and the wide range of synthetic techniques available have ensured that these materials can be tuned to adopt specific conformation or modified to contain specific functional groups. Our major focus in this thesis is developing peptid...
Operation Warp Speed: implications for global vaccine security
Kim, J. H.; Hotez, P.; Bottazzi, M. E.; Lall, B.; Sheahan, T.; Shoham, S.; Yadav, P.; Batista, C.; Ergonul, O.; Gürsel, Mayda; Figueroa, J. P.; Gilbert, S.; Larson, H.; Wilder-Smith, A.; Hassanain, M.; Kang, G.; Naniche, D.; Strub-Wourgaft, N. (2021-07-01)
Several global efforts are underway to develop COVID-19 vaccines, and interim analyses from phase 3 clinical testing have been announced by nine organisations: Pfizer, the Gamaleya Research Institute of Epidemiology and Microbiology, Moderna, AstraZeneca, Sinopharm Group, Sinovac Biotech, Johnson & Johnson, Novavax, and CanSino Biologics. The US programme known as Operation Warp Speed provided US$18 billion in funding for development of vaccines that were intended for US populations. Depending on safety and...
From RNA isolation to microarray analysis: Comparison of methods in FFPE tissues
Belder, Nevin; Coskun, Oznur; ERDOĞAN, BEYZA DOĞANAY; İlk Dağ, Özlem; SAVAŞ, BERNA; ENSARİ, ARZU; ÖZDAĞ, Hilal (Elsevier BV, 2016-01-01)
Background: Genome-wide gene expression profiling analysis of FFPE tissue samples is indispensable for cancer research and provides the opportunity to evaluate links between molecular and clinical information, however, working with FFPE samples is challenging due to extensive cross-linking, fragmentation and limited quantities of nucleic acid. Thus, processing of FFPE tissue samples from RNA extraction to microarray analysis still needs optimization.
The effects of twelve quorum-sensing gene products on the expression of bacabcde operon in bacillus subtilis
Öğülür, İsmail; Özcengiz, Gülay; Department of Biotechnology (2008)
In Bacillus subtilis, genetic competence, sporulation and antibiotic production are controlled by quorum-sensing global regulatory mechanism. Bacilysin, being produced and excreted by certain strains of Bacillus subtilis, is a dipeptide antibiotic composed of L-alanine and L-anticapsin. We showed that the biosynthesis of bacilysin is under the control of quorum sensing global regulatory pathway through the action of ComQ/ComX, PhrC (CSF), ComP/ComA in a Spo0K (Opp)-dependent manner. Recently, the ywfBCDEF g...
Providing Semantic Interoperability Between Clinical Care and Clinical Research Domains
Laleci, Gokce Banu; Yuksel, Mustafa; Doğaç, Asuman (2013-03-01)
Improving the efficiency with which clinical research studies are conducted can lead to faster medication innovation and decreased time to market for new drugs. To increase this efficiency, the parties involved in a regulated clinical research study, namely, the sponsor, the clinical investigator and the regulatory body, each with their own software applications, need to exchange data seamlessly. However, currently, the clinical research and the clinical care domains are quite disconnected because each use ...
Citation Formats
İ. Eren Vural, M. Herder, and J. E. Graham, “From sandbox to pandemic: Agile reform of Canadian drug regulation,” Health Policy, vol. 125, no. 9, pp. 1115–1120, 2021, Accessed: 00, 2022. [Online]. Available: